Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis
Open Access
- 1 January 2004
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 63 (6), 1010-1013
- https://doi.org/10.1016/j.mehy.2004.04.022
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults [published erratum appears in Blood 1994 Nov 15;84(10):3602]Blood, 1994
- Bone metastases: pathophysiology and management policy.Journal of Clinical Oncology, 1991
- Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.Proceedings of the National Academy of Sciences, 1987
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889